Get startedLog in
    Picture of Egetis Therapeutics AB (publ) logo

    EGTX — Egetis Therapeutics AB (publ) Income Statement

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapSucker Stock
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Egetis Therapeutics AB (publ), fiscal year end - December 31st, SEK millions except per share, conversion factor applied.

    R2020
    December 31st
    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue40.738.222.657.646.1
    Cost of Revenue
    Gross Profit38.830.416.346.634.5
    Selling / General / Administrative Expenses
    Research And Development
    Depreciation and Amortization
    Other Operating Expenses
    Total Operating Expenses218144221382376
    Operating Profit-177-106-198-325-329
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes-178-105-194-327-343
    Provision for Income Taxes
    Net Income After Taxes-178-105-194-327-344
    Net Income Before Extraordinary Items
    Net Income-178-105-194-327-344
    Adjustments to Net Income
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income-178-105-194-327-344
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-2.42-0.581-0.998-1.27-1.12
    Dividends per Share